Medbanks
思 派 健 康 科 技

Sipai Health Technology Co., Ltd.
思派健康科技有限公司

(A company incorporated in the Cayman Islands with limited liability)
(Stock Code: 0314)

POSITIVE PROFIT ALERT – NARROWING OF LOSS

This announcement is made by Sipai Health Technology Co., Ltd. (the "**Company**", together with its subsidiaries and consolidated affiliated entities, the "**Group**") pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the "**Board**") of directors (the "**Director(s)**") of the Company wishes to inform the shareholders (the "**Shareholders**") and potential investors of the Company that, based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the year ended December 31, 2025 (the "**FY2025**") and the information currently available to the Board, the Group expects that:

1) the normalized net loss[1] for the year will be significantly narrowed by more than 60% to no more than RMB50 million as compared to that of RMB127 million in 2024;

2) the net loss for the year will be significantly narrowed by more than 64% to no more than RMB130 million as compare to that of RMB362 million in 2024.

The significant narrowing of the normalized net loss and net loss was primarily due to (i) the strong growth achieved by the Group's core businesses, namely the corporate insurance services business and the physician research support business; (b) the effective restructuring of the specialty pharmacy business; and (c) the reduction in selling and administrative expense ratios resulting from a series of quality-enhancement and efficiency-improvement initiatives.

1 The normalized net loss is calculated as net loss (based on the International Financial Reporting Standards (IFRSs)) deducting non-recurring and non-operational items that we believe do not reflect the ongoing operating performance. For the year of 2025, such items mainly include (i) share-based payment compensation; (ii) restructuring cost; (iii) loss on disposal of subsidiaries; (iv) impairment loss of goodwill; and (v) non-recurring government grant.

The Company is still in the process of finalizing the annual results of the Group for the FY2025. The information contained in this announcement is only a preliminary assessment by the Board based on the figures and information currently available to the Board as at the date of this announcement, and is not audited or reviewed by the auditors and/or the audit committee of the Company and may differ from the actual annual results of the Group for the FY2025. Shareholders and potential investors of the Company should refer to and carefully read the annual results announcement of the Company for the FY2025, which is expected to be published in March 2026.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Sipai Health Technology Co., Ltd.
MA Xuguang
Chairman of the Board and Executive Director

Hong Kong, February 26, 2026

As at the date of this announcement, the Board comprises Mr. MA Xuguang and Mr. LI Ji as executive directors, Mr. YAO Leiwen as non-executive director, Mr. FAN Xin, Mr. HE Haijian and Ms. HUANG Bei as independent non-executive directors.